RT Journal Article
SR Electronic
T1 Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.18.20071167
DO 10.1101/2020.04.18.20071167
A1 Chang, Raymond
A1 Sun, Wei-Zen
YR 2020
UL http://medrxiv.org/content/early/2020/04/23/2020.04.18.20071167.abstract
AB Since the SARS-CoV-2 outbreak rapidly evolved into a pandemic, there is an urgent need for rapid development, identification and confirmation of efficacious antiviral prophylaxis. In this setting, the existing drugs chloroquine (CQ) and hydroxychloroquine (HCQ) which has suggestive evidence of efficacy against SARS-CoV-2 infection and COVID-19 disease has become prime candidates to be repositioned as therapeutic and preventative agents, and a growing number of clinical trials have been registered to study their preventative potential for at-risk populations using a range of dosing schemes and outcome measures. This rapid systematic review protocol aims to provide streamlined and timely synthesis on methodologies and results of randomized controlled trials assessing the efficacy of CQ and HCQ in hopes that this will constructively inform further research as well as public health policy.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://inplasy.com/inplasy-2020-4-0101/ Funding StatementThere is no funding support for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo data are associated with this articleCOVID-19coronavirus 2019CQchloroquineHCQhydroxychloroquineRCTrandomized controlled trialSARS-CoV-2severe acute respiratory syndrome coronavirus-2